Ponatinib in Japanese patients with Philadelphia chromosome-positive leukemia, a phase 1/2 study-Reference-Cited by-同舟云学术

Ponatinib in Japanese patients with Philadelphia chromosome-positive leukemia, a phase 1/2 study

Published:2017-04-25 Issue:3 Volume:106 Page:385-397
ISSN:0925-5710
Container-title:International Journal of Hematology
language:en
Short-container-title:Int J Hematol

Author:

Tojo Arinobu^ORCID,Kyo Taiichi,Yamamoto Kazuhito,Nakamae Hirohisa,Takahashi Naoto,Kobayashi Yukio,Tauchi Tetsuzo,Okamoto Shinichiro,Miyamura Koichi,Hatake Kiyohiko,Iwasaki Hiromi,Matsumura Itaru,Usui Noriko,Naoe Tomoki,Tugnait Meera,Narasimhan Narayana I.,Lustgarten Stephanie,Farin Heinrich,Haluska Frank,Ohyashiki Kazuma

Funder

ARIAD Pharmaceuticals, Inc., Cambridge, MA, USA

Publisher

Springer Science and Business Media LLC

Subject

Hematology

Link

http://link.springer.com/article/10.1007/s12185-017-2238-9/fulltext.html

Reference25 articles.

1. Au WY, Caguioa PB, Chuah C, Hsu SC, Jootar S, Kim DW, et al. Chronic myeloid leukemia in Asia. Int J Hematol. 2009;89:14–23.

2. Kantar Health. Treatment Architecture: Japan-Leukemia, Chronic Myelogenous. CancerMPact® Japan, V1.4; 2013 (October 2014).

3. Deininger M, O’Brien SG, Guilhot F, Goldman JM, Hochhaus A, Hughes TP, et al. International randomized study of interferon vs STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib. Blood. 2009;114:1126 (abstract).